Skip to main content
Công ty Cổ phần Dược phẩm Imexpharm logo

Công ty Cổ phần Dược phẩm Imexpharm — Investor Relations & Filings

Ticker · IMP ISIN · VN000000IMP0 HSX Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2023-09-15 Share Issue/Capital Cha…
Country VN Viet Nam
Listing HSX IMP

About Công ty Cổ phần Dược phẩm Imexpharm

www.imexpharm.com

Imexpharm Corporation is a prominent pharmaceutical company with over 48 years of experience in the manufacturing, compounding, and distribution of high-quality pharmaceutical products. The company operates extensive production facilities, including three EU-GMP certified factory clusters and one WHO-GMP certified cluster, making it a leader in EU-GMP compliant manufacturing. Imexpharm is recognized as a top producer of antibiotics and offers a diverse product portfolio encompassing injectable and oral antibiotics, cardiovascular, ophthalmic, musculoskeletal, respiratory, and digestive system treatments, alongside vitamins, minerals, and health protection foods. With 28 product registrations for 11 products in Europe, Imexpharm is dedicated to delivering effective and safe healthcare solutions to the community.

Recent filings

Filing Released Lang Actions
IMP: Thông báo về việc phát hành cổ phiếu để trả cổ tức năm 2022
Share Issue/Capital Change Classification · 92% confidence The document is a company disclosure filed on the State Securities Commission and Ho Chi Minh Stock Exchange portals, titled “Notice Issuance of Shares to Pay Dividends.” It lays out the plan and details for issuing shares as a dividend for 2022 (number of shares, issue ratio, record date, etc.). This is an announcement of a share issuance/capital change event rather than a financial report or dividend amount alone. It therefore fits the “Share Issue/Capital Change” category (SHA).
2023-09-15 Vietnamese
IMP: Công bố văn bản của UBCK nhận đầy đủ tài liệu báo cáo phát hành cổ phiếu để trả cổ tức năm 2022
Share Issue/Capital Change Classification · 90% confidence The document is an official company disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange regarding the receipt of the report documents for Imexpharm’s issuance of shares to pay 2022 dividends. It is not a full financial report, earnings release, or management discussion, but rather an announcement of a share issuance (capital change) to satisfy dividend payments. Therefore it fits the SH A category for share issue/capital change.
2023-09-13 Vietnamese
IMP: Nghị quyết HĐQT về phương án trả cổ tức bằng cổ phiếu năm 2022
Share Issue/Capital Change Classification · 90% confidence The document is a formal disclosure to Vietnam’s State Securities Commission and Ho Chi Minh Stock Exchange containing the full Board of Directors resolution on closing the shareholder register to pay 2022 dividends and implementing a share issuance plan to increase charter capital by issuing new shares as stock dividends. It provides detailed terms of the issuance (share symbol, number of shares, par value, ratio, timing) and authorizes filing procedures. This is not a simple dividend notice, management change, or regular financial report, but a capital change through new share issuance. Therefore it falls under “Share Issue/Capital Change” (SHA).
2023-08-15 Vietnamese
IMP: Nghị quyết HĐQT về việc thông qua BCTC và sơ đồ tổ chức
Regulatory Filings Classification · 80% confidence The document is a mandatory “24h” disclosure of a Board of Directors’ resolution filed on the State Securities Commission and Ho Chi Minh Stock Exchange portal. It includes the text of the BOD resolution approving the mid-year reviewed financial statements and corporate restructuring, but it does not itself contain financial statements, an earnings summary, or detailed ESG/governance code. It is neither an initial earnings release nor a full interim report, but a regulatory announcement of a board decision. It therefore best fits the “General Regulatory Filings” fallback category (RNS).
2023-08-15 Vietnamese
IMP: Giải trình chênh lệch LNST 6T/2023 so với cùng kỳ năm trước
Regulatory Filings Classification · 75% confidence The document is a compliance submission to the State Securities Commission and Ho Chi Minh Stock Exchange providing an explanation for more than 10% fluctuations in half-year financial results. It is not a standalone earnings release or interim report but a regulatory disclosure explaining changes in financial metrics, matching the general regulatory announcements category. Therefore, it falls under Regulatory Filings (RNS).
2023-08-10 Vietnamese
IMP: Báo cáo tình hình quản trị công ty 6 tháng đầu năm 2023
Governance Information Classification · 85% confidence The document is a disclosure to the State Securities Commission and Ho Chi Minh Stock Exchange titled “Report on Corporate Governance – First 6 Months of 2023.” It details the company’s governance model, Board of Directors’ activities, resolutions, and supervisory processes, rather than presenting full interim financial statements or initial earnings highlights. This aligns with the definition of a Governance Information report (CGR).
2023-07-28 Vietnamese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.